Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
André Scheen
Diabetes & Metabolism (2019) Vol. 45, Iss. 3, pp. 213-223
Closed Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 570
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Robert F. Schwabe, Ira Tabas, Utpal B. Pajvani
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1913-1928
Open Access | Times Cited: 482
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Lucas Opazo-Ríos, Sebastián Mas, Gema Marín‐Royo, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2632-2632
Open Access | Times Cited: 243
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 168
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Abdulrahman Ismaiel, Dan L. Dumitraşcu
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 152
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 16
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 916-927
Closed Access | Times Cited: 15
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
Alessandro Mantovani, Christopher D. Byrne, Eleonora Scorletti, et al.
Diabetes & Metabolism (2020) Vol. 46, Iss. 6, pp. 427-441
Open Access | Times Cited: 109
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, et al.
Metabolites (2020) Vol. 11, Iss. 1, pp. 22-22
Open Access | Times Cited: 102
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 79
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5863-5863
Open Access | Times Cited: 76
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Ajay Duseja, Shivaram Prasad Singh, Arka De, et al.
Journal of Clinical and Experimental Hepatology (2022) Vol. 13, Iss. 2, pp. 273-302
Open Access | Times Cited: 47
Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
Rosalba La Grotta, Chiara Frigé, Giulia Matacchione, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12325-12325
Open Access | Times Cited: 38
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
Stefano Ciardullo, Michela Vergani, Gianluca Perseghin
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5597-5597
Open Access | Times Cited: 33
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions
Stefano Ciardullo, Emanuele Muraca, Michela Vergani, et al.
Gastroenterology report (2023) Vol. 12
Open Access | Times Cited: 30
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeong Jun Song
Nutrients (2023) Vol. 15, Iss. 18, pp. 3970-3970
Open Access | Times Cited: 22
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Xiaodan Lv, Yongqiang Dong, Lingling Hu, et al.
Endocrinology Diabetes & Metabolism (2020) Vol. 3, Iss. 3
Open Access | Times Cited: 51
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
João Victor da Silva Guerra, Marieli M. G. Dias, Anna Julyana Viana Chianca Brilhante, et al.
Nutrients (2021) Vol. 13, Iss. 8, pp. 2830-2830
Open Access | Times Cited: 48
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 31
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Mona Mashayekhi, Bilgunay Ilkin Safa, Matthew S.C. Gonzalez, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 5, pp. 425-438
Closed Access | Times Cited: 5
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 5
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review
Liana Iordan, Laura Gaiţă, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 5
Sodium-Glucose Transport Protein-2 Inhibitors in the Treatment of Non-alcoholic Steatohepatitis: An Evidence-Based Review
Xueyan Lv, Dianchao Mi Mi, Yan Xin, et al.
Hepatitis Monthly (2025) Vol. 25, Iss. 1
Open Access
Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations
Marco Arrese, Francisco Barrera, Nicolás Triantafilo, et al.
Expert Review of Gastroenterology & Hepatology (2019) Vol. 13, Iss. 9, pp. 849-866
Closed Access | Times Cited: 49
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih‐Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top